Overview

CV Events in Emetogenic Chemotherapy

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
0
Participant gender:
All
Summary
Describe cardiovascular events in a cancer population receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Emetics
Criteria
Inclusion Criteria:

- Enrollment in IHCIS in 2006

- At least one HEC or MEC claim in 2006

Exclusion Criteria:

- HEC or MEC claim three months before first HEC/MEC claim - "wash-in" period (i.e. must
be enrolled for three months prior to first HEC/MEC claim. For patients whose first
HEC/MEC event is between January 1,2006 and March 31, 2006, enrollment criteria for
inclusion in the study may extend as far back as October 1, 2005)

- HEC or MEC claims prior to 45 days after last HEC or MEC claim - "wash-out" period.
(For patients whose last claim in 2006 was seen after December 1, 2006 enrollment into
2007 to look for further treatment and the 45 day "wash-out" period will be required.)